-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $400

Benzinga·09/21/2026 17:43:05
Diffusion vocale
B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $392 to $400.